Hi C. I'm a buyer, slowly. Good pipeline. Good preclinical data. Early still - but already improvement on the field. I'm all about next gen protein tech right now. Early tech in the field produced limited, overly specific agents with significantly higher risk of provoking undesired immune responses but enough time has passed and the newer tech touches diverse targets/diverse diseases with minimal to no unwanted intrusion, decreased to negligible undesired immunogenicity. Cheaper to produce. Safer. Expanding treatable disease targets. I like the company. Good management. They execute. Good financial management. Part of their pipeline development was comparison based against other therapeutic protein technology and against monoclonal antibody tech. They id'd very detailed weakness of both and created preclinical and clinical goals which included measuring performance of their tech against the others, getting very specific in outperforming in the identified trouble areas. Smart use of the weaknesses of technologies that are bringing in a ton of money right now. They want to prove from the opening gate that theirs is refined, new, safer. They'll need to do this in order to loosen the hold monoclonal antibodies have on the market.
I'm buying in the 2.50s for as long as I can. Do think we'll have a couple of dips there over next few weeks.
Also - buying AVXL for same reason. Protein tech. Corrects protein misfolding errors which are associated with countless dread diseases. Spike today on good news but it'll float back down. Watching for Treventis to go public. Protein folding correction tech targeting many brain based diseases but also has developed a system that id's and constructs models of misfolded protein structures in order to screen new protein drug candidates for perfect structure based design. Everyone will want this, including Pieris.
That's it for now C!
Take care!
